Statins have been proposed as a potential treatment for systemic lupus erythematosus (SLE) due to their immunomodulatory properties, their role restoring endothelial function and preventing atherosclerosis. We evaluate the effect of a short period treatment with a low dose of atorvastatin and its withdrawal on early stage subclinical atherosclerosis.
Methods
Thirty-seven SLE females received 20 mg/day atorvastatin during eight weeks. At baseline, at the end of treatment and six months after atorvastatin withdrawal, disease activity, subclinical atherosclerosis –assessed by measuring carotid-femoral pulse wave velocity (PWV) – and quantification of circulating endothelial progenitor cells (EPC) – as a surrogate biological marker of subclinical atherosclerosis – were carried out.
Results
The group of SLE patients with baseline pathological arterial stiffness showed a significant decrease of PWV after atorvastatin therapy (8.43 ± 1.45 m/s vs 7.42 ± 1.06 m/s; p = 0.002) that is maintained six months after treatment finished. Only patients of the middle-aged group showed a nearly significant decrease in the PWV measured along the study (7.16 ± 1.23 m/s vs 6.76 ± 0.82 m/s; p = 0.05). Atorvastatin induced a significant decrease in the circulating EPC percentage (0.65 ± 0.67 vs 0.40 ± 0.31; p = 0.023) as well as a downward trend of disease activity that it is observed by a decrease in SLE disease activity index simultaneously with an increase in C3 complement and significant decrease in serum concentration of vascular endothelial grow factor (VEGF) and sVCAM-1.
Conclusions
Short-term atorvastatin therapy reduces arterial stiffness of SLE patients with baseline pathological PWV, who are mainly in the group of middle-aged patients. Further studies are needed to determine whether these patients would benefit from statin therapy in preventing cardiovascular events.
Abu-ShakraMUrowitzMBGladmanDDGoughJ. Mortality studies in systemic lupus erythematosus. Results from a single centre I. Causes of death. J Rheumatol1995; 22: 1259–1264.
2.
BernatskySBoivinJ-FJosephL, et al.Mortality in systemic lupus erythematosus. Arthritis Rheum2006; 54: 2550–2557.
3.
PetriMPerez-GutthannSSpenceDHochbergM. Risk factors for coronary artery disease in patients with systemic lupus erythematosus. Am J Med1992; 93: 513–519.
4.
ManziSMeilahnERairieJ, et al.Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with Framingham study. Am J Epidemiol1997; 145: 408–415.
5.
RahmanPUrowitzMGladmanDBruceINGenestJJr. Contribution of traditional risk factors to coronary artery disease in patients with systemic lupus erythematosus. J Rheumatol1999; 26: 2363–2368.
6.
EsdaileJAbrahamowiczMGrodzickyT, et al.Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum2001; 44: 2331–2337.
7.
WesterweelPELuijtenRKHoeferIEKoomansHADerksenRHVerhaarMC. Haematopoietic and endothelial progenitor cells are deficient in quiescent systemic lupus erythematosus. Ann Rheum Dis2007; 66: 865–870.
8.
LeePYLiYRichardsHB, et al.Type I interferon as a novel risk factor for endothelial progenitor cell depletion and endothelial dysfunction in systemic lupus erythematosus. Arthritis Rheum2007; 56: 3759–3769.
9.
MoonenJRde LeeuwKvan SeijenXJ, et al.Reduced number and impaired function of circulating progenitor cells in patients with systemic lupus erythematosus. Arthritis Res Ther2007; 9: R84–R84.
10.
EbnerPPicardFRichterJ, et al.Accumulation of VEGFR-2+/CD133+ cells and decreased number and impaired functionality of CD34+/VEGFR-2+ cells in patients with SLE. Rheumatology2010; 49: 63–72.
11.
AsaharaTMuroharaTSullivanA, et al.Isolation of putative progenitor endothelial cells for angiogenesis. Science1997; 275: 946–947.
12.
PeichevMNaiyerAJPereiraD, et al.Expresion of VEGFR-2 and AC 133 by circulating human CD34(+) cells identifies a population of functional endothelial precursors. Blood2000; 95: 952–958.
13.
LaurentSBoutouyriePAsmarR, et al.Aortic stiffness is an independent predictor of all-cause and cardiovascular mortality in hypertensive patients. Hypertension2001; 37: 1236–1241.
14.
Mattace-RasoFUSvan der CammenTJMHofmanA, et al.Arterial stiffness and risk of coronary heart disease and stroke: The Rotterdam Study. Circulation2006; 113: 657–663.
15.
MitchellGFHwangSVasanRS, et al.Arterial stiffness and cardiovascular events: The Framingham Heart Study. Circulation2010; 121: 505–511.
16.
WernerNKoisolSSchieglT, et al.Circulating Endothelial Progenitor Cells and Cardiovascular Outcomes. N Engl J Med2005; 353: 999–1007.
17.
CastejonRJimenez-OrtizCValero-GonzalezSRosadoSMellorSYebra-BangoM. Decreased circulating endothelial progenitor cells as an early risk factor of subclinical atherosclerosis in systemic lupus erythematosus. Rheumatology2014; 53: 631–638.
18.
ShepheredJCobbeSMFordI, et al.Prevention of coronary heart disease with pravastatin in men with hypercolesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med1995; 330: 1301–1307.
19.
WOSCOPS Study Group. Influence of pravastatin and plasma lipids on clinical events in the West of Scotland coronary prevention study (WOSCOPS). Circulation1998; 97: 1440–1445.
20.
BallantyneCMHerdJADunnJKJonesPHFarmerJAGottoAMJ. Effects of lipid lowering therapy on progression of coronary and carotid artery disease. Curr Opin Lipidol1997; 8: 354–361.
21.
CrisbyMNordin-FredrikssonGShahPKYanoJZhuJNilssonJ. Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques: implications for plaque stabilization. Circulation2001; 103: 926–933.
22.
VasaMFichtlschererSAdlerK, et al.Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation2001; 103: 2885–2890.
23.
SinghUDevarajSJialalISiegelD. Comparison effect of atorvastatin (10 versus 80 mg) on biomarkers of inflammation and oxidative stress in subjects with metabolic syndrome. Am J Cardiol2008; 102: 321–325.
24.
FerreiraGANavarroTPTellesRWAndradeLECSatoEI. Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial. Rheumatology2007; 46: 1560–1565.
25.
PetriMKianiANPostWChristopher-StineLMagderLS. Lupus Atherosclerosis Prevention Study (LAPS). Ann Rheum Dis2011; 70: 760–765.
26.
PlazakWGrygaKDziedzicH, et al.Influence of atorvastatin on coronary calcifications and myocardial perfusion defects in systemic lupus erythematosus patients: a prospective, randomized, double-masked, placebo-controlled study. Arthritis Res Ther2011; 13: R117–R117.
27.
MokCCWongCKToCHShan LaiJPSum LamC. Effects of rosuvastatin on vascular biomarkers and carotid atherosclerosis in lupus: a randomized, double-blind, placebo-controlled trial. Arthritis Care Res2011; 63: 875–883.
28.
SchanbergLESandborgCBarnhartHX, et al.Use of atorvastatin in systemic lupus erythematosus in children and adolescents. Arthritis Rheum2012; 64: 285–296.
29.
DistlerJAllanoreYAvouacJ, et al.EUSTAR statment and recommendations on endothelial precursor cells. Ann Rheum Dis2009; 68: 163–168.
30.
AsanumaYChungCOeserA, et al.Increased concentration of proatherogenic inflammatory cytokines in systemic lupus erythematosus: relationship to cardiovascular risk factors. J Rheumatol2006; 33: 539–545.
31.
RhoYHChungCPOeserA, et al.Novel cardiovascular risk factors in premature coronary atherosclerosis associated with systemic lupus erythematosus. J Rheumatol2008; 35: 1789–1794.
32.
References values for arterial stiffness collaboration. Determinants of pulse wave velocity in healthy people and in the presence of cardiovascular risk factors: ‘establishing normal and references values’. Eur Heart J2010; 31: 2338–2350.
33.
SmidleTJVan Den BerkmortelFWWollersheimHvan LangenHKasteleinJJStalenhoefAF. The effect of cholesterol lowering on carotid and femoral artery wall stiffness and thickness in patients with familial hypercholesterolaemia. Eur J Clin Invest2000; 30: 473–480.
34.
FerrierKEMuhlmannMHBaguetJP, et al.Intensive cholesterol reduction lowers blood pressure and large artery stiffness in isolated systolic hypertension. J Am Coll Cardiol2002; 39: 1020–1025.
35.
LunderMJanicaMHabjanaSSabovicM. Subtherapeutic, low-dose fluvastatin improves functional and morphological arterial wall properties in apparently healthy, middle-aged males – a pilot study. Atherosclerosis2011; 215: 446–451.
36.
RatchfordEVGutierrezJLorenzoD, et al.Short-term effect of atorvastatin on carotid artery elasticity: a pilot study. Stroke2011; 42: 3460–3464.
37.
ChironiGWalchLPernolletMG, et al.Decreased number of circulating CD34+KDR cells in asymptomatic subjets with preclinical atherosclerosis. Atherosclerosis2007; 191: 115–120.
38.
HibbertBSimardTRamirezD, et al.The effect of statins on circulating endothelial progenitor cells in humans: a systematic review. J Cardiovasc Pharmacol2013; 62: 491–496.
39.
HristovMFachCBeckerC, et al.Reduced numbers of circulating endothelial progenitor cells in patients with coronary artery disease associated with long-term statin treatment. Atherosclerosis2007; 192: 413–420.
40.
Ruiz-LimonPBarbarrojaNPerez-SanchezC, et al.Atherosclerosis and cardiovascular disease in systemic lupus erythematosus: effects of in vivo statin treatment. Ann Rheum Dis2015; 74: 1450–1458.
41.
FernándezMMcGwinGAndradeR, et al.Systemic lupus erythematosus in a multiethnic US cohort, LUMINA (XLIX): Preliminary Evaluation of the Impact of Statins on Disease Activity. J Clin Rheumatol2008; 14: 178–180.
42.
KotylaPJSliwinska-KotylaBKucharzEJ. Tumor necrosis factor-alpha as a potential target in the treatment of systemic lupus erythematosus: a role for the HMG-CoA reductase inhibitor simvastatin. J Rheumatol2006; 33: 2361–2363.
43.
FadiniGPRigatoMBoscariF, et al.Short-term statin discontinuation increases endothelial progenitor cells without inflammatory rebound in type 2 diabetic patients. Vascul Pharmacol2015; 67–69: 21–29.
